Accueil > PORTAL > Psoriasis: consensus and controversies > Groupe de Recherche sur le Psoriasis de la Société Française de (...) > Conférences annuelles >
Conférences annuelles
Introduction
La réunion scientifique du groupe français du psoriasis a lieu une fois par an, sauf l’année du congrès international du Psoriasis qui a lieu tous les (...)
Programme de la conférence du 17 novembre 2006
La réunion a eu lieu au Ministère de l’Education Nationale, de l’Enseignement Supérieur et de la Recherche, Amphithéâtre Poincaré, 1, rue Descartes, (...)
Diaporamas des conférences du 17 novembre 2006
Le syndrome métabolique existe-t-il ? Prof. Jean-Jacques Mourad
Apport de la microscopie dans la compréhension et le diagnostic du psoriasis - (...)
Second congrès international sur le psoriasis
En 2007, il y a eu le second congrès international sur le psoriasis. Ce congrès réunit tous les groupes psoriasis et est organisé tous les 3 ans à (...)
2nde Journée du Groupe Français du Psoriasis
Cette journée a eu lieu le jeudi 23 octobre 08, au Musée des Moulages de l’Hôpital Saint-Louis à Paris, 1 avenue Claude vellefaux, 75010.
Le (...)
Diaporamas des conférences de la 2nde Journée du Psoriasis
Cliquer sur la conférences que vous souhaiter consulter.
Introduction - Louis Dubertret
Actualités sur le rhumatisme psoriasique - Thomas Bardin (...)
3ème Journée du Groupe Français du Psoriasis
Cette journée a eu lieu le vendredi 16 octobre 09, au Musée des Moulages de l’Hôpital Saint-Louis à Paris, 1 avenue Claude vellefaux, 75010.
Le (...)
Diaporamas des conférences de la 3ème Journée du Psoriasis
Cliquer sur la conférences que vous souhaiter consulter.
PSORIASIS, GROSSESSE ET CONTRACEPTION - Selim Aractingi
PARTICULARITES DU PSORIASIS DE (...)
4ème Journée du Groupe Français du Psoriasis
Cette journée a obtenu un agrément FMC
PSORIASIS 2010 : UNE APPROCHE TRANSDISCIPLINAIRE
aura lieu le vendredi 29 octobre 10, au Musée des (...)
Diaporamas des conférences de la 4ème Journée du Psoriasis
Cliquer sur la conférences que vous souhaiter consulter.
MANIFESTATIONS HEPATO-BILIAIRES OBSERVEES AU COURS DU PSORIASIS - Manuelle Viguier et (...)
5ème Journée du Groupe de Recherche sur le Psoriasis
Cette journée a obtenu un agrément FMC
LE PSORIASIS DANS TOUS SES ETATS
a eu lieu le vendredi 7 octobre 11, à l’Institut Pasteur, Paris.
Programme (...)
Diaporamas des conférences de la 5ème Journée du Psoriasis
Cliquer sur les conférences que vous souhaiter consulter.
INTRODUCTION- H. Bachelez
TRAITEMENT DU PSORIASIS DE L’ENFANT - S. Barbarot (Nantes) (...)
10ème Journée du Groupe de Recherche sur le Psoriasis
Cliquez sur l’image pour avoir accès au programme détaillé de la 10ème journée scientifique annuelle du Groupe de Recherche sur le Psoriasis du 18 (...)
SPIN Presentation
Recent news
- 2019/10/29 Focus on...
- 2019/08/12 Focus on...
Latin American Clinical Practice Guidelines on the Systemic Treatment of Psoriasis
- 2019/06/03 Focus on...
- 2019/05/21 Focus on...
Prof Nelida Aurora Raimondo
News from the web office
- 2016/10/29
- 2016/05/26
- 2016/02/20
Events
- 2019/04/18 Focus on...
- 2018/02/21
News from medical groups
- 2018/04/18
- 2017/06/21
News from patients associations
- 2017/02/08
- 2016/05/26
Recent publications on Psoriasis and Atopic Dermatitis
on Psoriasis
Discovery of benzo[f]pyrido[4,3-b][1,4]oxazepin-10-one derivatives as orally available bromodomain and extra-terminal domain (BET) inhibitors with efficacy in an in vivo psoriatic animal model.
Bioorg Med Chem.
2021 Mar 15, 34:116015.
Bromodomain and extra-terminal domain (BET) protein plays an important role in epigenetic regulation, and the regulation of disruption contributes to the pathogenesis of cancer and inflammatory disease. With the goal of discovering novel BET inhibitors, especially BRD4 inhibitors, we designed and synthesized several compounds starting from our previously reported pyrido-benzodiazepinone derivative 4 to enhance BRD4 inhibitory activity while avoiding hERG inhibition. Molecular docking (...)
see on pubmed
Clinical trait-connected network analysis reveals transcriptional markers of active psoriasis treatment with Liangxue-Jiedu decoction.
J Ethnopharmacol.
2021 Mar 25, 268:113551.
Psoriasis is a complex recurrent inflammatory skin disease with different pathological changes in different stages. Psoriasis in its active stage, which is comparable to the blood-heat type in traditional Chinese medicine (TCM), has been treated by Liangxue Jiedu Decoction (LJD) in TCM for decades, with proven efficacy. According to TCM theories, LJD has the function of removing heat and pathogenic factors from the (...)
see on pubmed
Catalpol ameliorates psoriasis-like phenotypes via SIRT1 mediated suppression of NF-κB and MAPKs signaling pathways.
Bioengineered.
2021 Dec , 12, (1):183-195.
Psoriasis is a chronic inflammatory skin disease that affects approximately 2% of worldwide population, and causing long-term troubles to the patients. Therefore, it is urgent to develop safe and effective therapeutic drugs. Catalpol is a natural iridoid glucoside, that has several remarkable pharmacological effects, however, whether catalpol can alleviated psoriasis has not been explored. The goal of the present work is to study the role of catalpol in psoriasis in vivo and in vitro. (...)
see on pubmed
on Atopic Dermatitis
Psychiatric and Nonpsychiatric Comorbidities Among Children With ADHD: An Exploratory Analysis of Nationwide Claims Data in Germany.
J Atten Disord.
2021 Apr , 25, (6):874-884.
This study examined the full spectrum of comorbid disorders in all statutory-health-insured children aged 5 to 14 years with ADHD in 2017 by using nationwide claims data in Germany. Children with ADHD ( = 258,662) were compared for the presence of 864 comorbid diseases with a control group matched by gender, age, and region of residence ( = 2,327,958). Among others, metabolic disorders (odds ratio [OR] = 9.18; 95% confidence interval [CI] = [8.43, 9.99]), viral pneumonia (OR = 4.95; 95% (...)
see on pubmed
Qingxue jiedu formulation ameliorated DNFB-induced atopic dermatitis by inhibiting STAT3/MAPK/NF-κB signaling pathways.
J Ethnopharmacol.
2021 Apr 24, 270:113773.
Qingxue jiedu Formulation (QF) is composed of two classic prescriptions which have been clinically used for more than 5 centuries and appropriately modified through basic theory of traditional Chinese medicine for treating various skin inflammation such as atopic dermatitis (AD), acute dermatitis and rash. Although QF possesses a prominent clinical therapeutic effect, seldom pharmacological studies on its anti-AD activity are (...)
see on pubmed
Methicillin-resistant from infected skin lesions present several virulence genes and are associated with the CC30 in Brazilian children with atopic dermatitis.
Virulence.
2021 Dec , 12, (1):260-269.
Atopic dermatitis (AD) is a chronic inflammatory skin disease and colonization by may affect up to 100% of these patients. Virulent and resistant isolates can worsen AD patient clinical condition and jeopardize the treatment. We aimed to detect virulence genes and to evaluate the biofilm production of isolates from infected skin lesions of children with AD. Methicillin resistance was detected by phenotypic and molecular tests and the virulence genes were detected by PCR. Biofilm formation (...)
see on pubmed